Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 4,312 | 871 | 3,366 |
| Samples | 2,780 | 539 | 2,193 |
| Peptides | 2,289 | 470 | 1,915 |
Function
MUC5B · Mucin 5B, oligomeric mucus/gel-forming
This gene encodes a member of the mucin family of proteins, which are highly glycosylated macromolecular components of mucus secretions. This family member is the major gel-forming mucin in mucus. It is a major contributor to the lubricating and viscoelastic properties of whole saliva, normal lung mucus and cervical mucus. This gene has been found to be up-regulated in some human diseases, including sinus mucosa of chronic rhinosinusitis (CRS), CRS with nasal polyposis, chronic obstructive pulmonary disease (COPD) and H. pylori-associated gastric disease, and it may be involved in the pathogenesis of these diseases. [provided by RefSeq, Jul 2010].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000529681 | Q9HC84 | 4,312 | 2,289 |
Gene Properties
Recurrent Mutations
All 2429 amino-acid changes on canonical ENST00000529681 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in MUC5B · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in MUC5B – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 20/40 50% | 0/0 0% |
| Glioblastoma | 27/98 28% | 0/0 0% |
| Chronic Myelogenous Leukemia | 5/25 20% | 0/0 0% |
| T-Cell Non-Hodgkins Lymphoma | 5/26 19% | 0/0 0% |
| Endometrial Carcinoma | 19/42 45% | 106/612 17% |
| Oral Cavity Carcinoma | 10/54 19% | 0/0 0% |
| Acute Myeloid Leukemia | 13/90 14% | 0/0 0% |
| Melanoma | 36/210 17% | 220/1899 12% |
| Non-Small Cell Lung Carcinoma | 52/304 17% | 131/1390 9% |
| Other Solid Cancers | 11/94 12% | 160/1515 11% |
| Squamous Cell Lung Carcinoma | 11/57 19% | 79/810 10% |
| Colorectal Carcinoma | 41/143 29% | 279/3239 9% |
| Cervical Carcinoma | 5/35 14% | 37/422 9% |
| Gastric Carcinoma | 15/74 20% | 132/1809 7% |
| Neuroendocrine Tumour | 38/154 25% | 15/577 3% |
| Chondrosarcoma | 6/14 43% | 0/75 0% |
| Small Cell Lung Carcinoma | 5/9 56% | 46/752 6% |
| Hodgkins Lymphoma | 4/16 25% | 5/122 4% |
| Esophageal Squamous Cell Carcinoma | 11/51 22% | 158/2550 6% |
| Rhabdomyosarcoma | 6/33 18% | 6/171 4% |
| Bladder Carcinoma | 6/58 10% | 50/956 5% |
| Thyroid Gland Carcinoma | 7/45 16% | 79/1592 5% |
| Biliary Tract Carcinoma | 5/54 9% | 46/950 5% |
| Chordoma | 1/7 14% | 0/13 0% |
| Mesothelioma | 7/62 11% | 4/165 2% |
| Head and Neck Carcinoma | 8/85 9% | 69/1574 4% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 6/133 5% |
| Ovarian Carcinoma | 20/109 18% | 25/998 3% |
| Non-Cancerous | 11/104 11% | 27/830 3% |
| Esophageal Carcinoma | 1/23 4% | 30/769 4% |
Mutation Distribution
Where MUC5B is mutated · all tissues, split by cell line vs tissue
How many mutations in MUC5B were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 4,312 mutations in MUC5B
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|